Welcome to our dedicated page for ContextLogic news (Ticker: LOGC), a resource for investors and traders seeking the latest updates and insights on ContextLogic stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ContextLogic's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ContextLogic's position in the market.
LogicBio Therapeutics (Nasdaq: LOGC) presented preclinical data on its GeneRide™ platform at the ESGCT Virtual Congress 2021, showcasing its potential in treating methylmalonic acidemia, hereditary tyrosinemia type 1, and Wilson disease. Findings indicated successful repopulation of diseased livers with corrected hepatocytes, demonstrating reduced toxic metabolite levels and improved liver function. The research highlights GeneRide's selective advantage in liver editing, with important implications for genetic medicine. Additional advancements in the company's AAV technology were also discussed.
LogicBio Therapeutics announced promising results from its Phase 1/2 SUNRISE clinical trial, showcasing the first-ever in vivo genome editing in children with methylmalonic acidemia (MMA). The early data indicated measurable levels of the albumin-2A biomarker, confirming gene insertion and protein expression. Based on the independent Data Safety Monitoring Board's recommendation, the trial will proceed to higher dosing cohorts. LB-001, the investigational therapy utilizing GeneRide™ technology, aims to offer a safe, effective treatment for MMA, a rare genetic disorder with no current therapies.
LogicBio Therapeutics (Nasdaq: LOGC) announced its selection to present new data from the GeneRide™ platform at the European Society of Gene and Cell Therapy (ESGCT) Virtual Congress 2021, occurring from October 19-22, 2021. The company will deliver a plenary oral presentation on preclinical data showing effective gene delivery in liver conditions, emphasizing the advantages in corrected hepatocyte repopulation. Additionally, three poster presentations will focus on advancements in treating Tyrosinemia Type 1 and optimizing AAV manufacturing processes.
LogicBio Therapeutics (Nasdaq: LOGC) announced that CEO Fred Chereau will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021, at 8:00 a.m. ET. The event will be accessible via a live webcast on the company's investors section of their website, with a replay available for 30 days. LogicBio Therapeutics focuses on gene editing and delivery to address rare diseases using innovative platforms like GeneRide™ and sAAVy™.
LogicBio Therapeutics, a clinical-stage genetic medicine company based in Lexington, MA, announced that its CEO, Fred Chereau, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting at 7:00 a.m. ET on September 13. The company focuses on gene editing and delivery platforms, including GeneRide for precise gene insertion and sAAVy for optimizing gene delivery.
LogicBio Therapeutics (Nasdaq: LOGC) reported Q2 2021 financial results with revenues of $0.8 million, down from $1.0 million YoY. R&D expenses increased to $7.3 million from $5.9 million, contributing to a net loss of $10.5 million or $0.33 per share. The company highlighted the dosing of the first patient in the SUNRISE trial for LB-001, aimed at treating methylmalonic acidemia (MMA). Strategic partnerships with Daiichi Sankyo and CANbridge Pharmaceuticals were formed, enhancing its GeneRide and sAAVy platforms.
LogicBio Therapeutics (Nasdaq:LOGC) announced that CEO Frederic Chereau will participate in a virtual panel on Delivery and Durability of Genetic Medicines at the William Blair Biotech Focus Conference 2021.
The event is scheduled for July 15, 2021, at 10:00 a.m. ET. LogicBio is a clinical-stage company focused on gene editing and delivery platforms aimed at treating rare diseases.
Their platforms include GeneRide™ for precise gene insertion and sAAVy™ for optimized gene delivery.
LogicBio Therapeutics (Nasdaq:LOGC) announced the first patient has been dosed with LB-001, a gene editing therapy for methylmalonic acidemia (MMA) in the SUNRISE Phase 1/2 clinical trial. Conducted at Monroe Carell Jr. Children's Hospital at Vanderbilt, this marks a key step in addressing MMA, a rare genetic disorder affecting 1 in 50,000 newborns. The trial aims to evaluate LB-001's safety and tolerability in pediatric patients aged 3-12, with future enrollment for infants as young as 6 months. LogicBio expects to announce interim clinical data by the end of 2021.
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) announced on June 1, 2021, that CEO Frederic Chereau will participate in virtual fireside chats at two investor conferences. The events include the Jefferies Virtual Healthcare Conference on June 4 at 9:30 AM ET and the JMP Securities Life Sciences Conference on June 16 at 2:00 PM ET. Interested parties can access live webcasts through the Investors section of the company's website. LogicBio focuses on pioneering gene delivery and editing platforms to address rare diseases, utilizing innovative technologies like GeneRide™ and sAAVy™.
LogicBio Therapeutics (Nasdaq: LOGC) announced the promotion of Dr. Daniel Gruskin to Chief Medical Officer and the appointment of Dr. Stephen Boyer as Vice President of Regulatory and Quality Affairs, along with Dr. Peter Pechan as Vice President of Gene Therapy. These leadership changes support ongoing advancements in the Phase I/II SUNRISE clinical trial of LB-001, an investigational treatment for methylmalonic acidemia (MMA). The new appointments come amidst recent collaborations with Daiichi Sankyo and CANbridge Pharmaceuticals.
FAQ
What is the current stock price of ContextLogic (LOGC)?
What is the market cap of ContextLogic (LOGC)?
